What is it about?
Saving lives on the battlefield and pre-hospital environments. The paper is a summary of the development of a new ALM drug therapy, which at high doses stops the heart for cardiac surgery, and at low doses bolsters the body's protection against different kinds of trauma and infection/sepsis.
Featured Image
Why is it important?
Around 90% of battlefield deaths occur before the combatant reaches a medical treatment facility. The "Golden Hour" does not exist. There are no effective drugs on the battlefield or pre-hospital medicine that treat severe bleeding, shock, traumatic brain injury, haemorrhagic shock, sepsis and burns.
Perspectives
We are developing a “One-Solution-Fits All” ALM therapy that bolsters the patient’s response to trauma, not treat the trauma stressor (injury, hemorrhage, pathogen or burn) itself. The ALM therapy is a new treatment concept in medicine and explains why the drug confers such widespread protection against traumatic brain injury, hemorrhagic shock, cardiac arrest, regional myocardial ischemia, arrhythmias, endotoxemia, infection, and sepsis. The drug appears to work by improving CNS control of cardiovascular-endothelium function, correcting coagulopathy and reducing inflammation. We believe its adoption will save lives on the battlefield and in prehospital urban, regional and rural and remote settings. The fluid is adminsitered intravenously at very low volumes and may be useful for one-punch victims, stroke, sport-related head injuries, post-partum hemorrhage and other trauma.
Dr Geoffrey P Dobson
James Cook University
Read the Original
This page is a summary of: Adenosine, lidocaine, and Mg2+ (ALM), Journal of Trauma and Acute Care Surgery, January 2016, Wolters Kluwer Health,
DOI: 10.1097/ta.0000000000000881.
You can read the full text:
Contributors
The following have contributed to this page
